Skip to main navigation
Skip to main content
Skip to Footer

Careers
Contact Us

Our Motivation
- Diseases & Conditions
- Patient Community
  - Patient Advocacy & Engagement
Our Science
- Our Pipeline
- Clinical Trials
- Funding & Support
Our Company
- About Us
- Corporate Social Responsibility
- Transfer of Value Reporting
Investors & Media

Search our website

Close

Our Motivation
- Diseases & Conditions
  - PKU
  - CLN2 Disease
  - MPS IVA
  - MPS VI
  - Achondroplasia
  - Haemophilia A
- Patient Community
  - Patient Advocacy & Engagement
Our Science
Our Company
Investors & Media

Privacy Policy & Notice of Information Practices
Cookie Preferences
Terms of Use
Slavery Act Statement
UK Tax Strategy
Site Map

© 2025 BioMarin. All rights reserved. Developed and funded by BioMarin.

Information for Investors and the Media

Media Enquiries

Global media enquiries please contact:

+1 (415) 506-6700

Investor Enquiries

Image: Person looking at charts on an ipad

Contact Us

Have a question or need to get in touch with us? We’re here.

Learn More our contact page ⌃

Global Compliance & Ethics

We conduct all aspects of our business in accordance with the highest standards of ethical behaviour.

Learn More Global Compliance & Ethics ⌃

Home
›
Investors & Media

Navigate
Our Motivation
Our Science
Our Company
Investors & Media
Careers

About
About Us
Diseases & Conditions
Our Pipeline
Transfer of Value Reporting
Funding & Support

Contact
Contact Us
Medical Information
Report a Possible Side Effect
Grants & Donations

Privacy Policy & Notice of Information Practices
Cookie Preferences
Terms of Use
Supply Chain Statement
UK Tax Strategy
Site Map

© 2025 BioMarin. All rights reserved. Developed and funded by BioMarin. EU-MDRL-00120 April 2023

You are about to leave the BioMarin.eu website and will be redirected to BioMarin’s global website owned and operated by our headquarters, BioMarin Pharmaceutical Inc., located in the United States. Please note that the BioMarin.com (US) website uses cookies to help personalise content, measure advertisements, and provide a safer user experience. By clicking “Proceed Anyway”, you will be automatically redirected to the BioMarin.com (US) website and agree to the use of cookies and similar technologies as described in the Privacy Policy and can manage your detailed cookie choices by clicking on Cookie Preferences. Otherwise, click “Return to BioMarin.eu”.

Proceed Anyway ⌃ Return to BioMarin.eu ⌃

You are about to leave the BioMarin.eu website. BioMarin makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information. Inclusion of any third party link does not imply an endorsement or recommendation by BioMarin.

OK ⌃ Cancel ⌃

You are about to leave the BioMarin.eu website and will be redirected to BioMarin’s global website owned and operated by our headquarters, BioMarin Pharmaceutical Inc., located in the United States. Please note that the BioMarin.com (US) website uses cookies to help personalise content, measure advertisements, and provide a safer user experience. By clicking “Proceed Anyway”, you will be automatically redirected to the BioMarin.com (US) website and agree to the use of cookies and similar technologies as described in the Privacy Policy and can manage your detailed cookie choices by clicking on Cookie Preferences. Otherwise, click “Return to BioMarin.eu”.

OK ⌃ Cancel ⌃

You are about to leave the BioMarin.eu corporate website for a BioMarin disease-focused website located in the United States. Inclusion of any third party link does not imply an endorsement or recommendation by BioMarin.

OK ⌃ Cancel ⌃